4 research outputs found
Efficacy of novel immunotherapy regimens in patients with metastatic melanoma with germline CDKN2A mutations
Inherited CDKN2A mutation is a strong risk factor for cutaneous melanoma. Moreover, carriers have been found to have poor melanoma-specific survival. In this study, responses to novel immunotherapy agents in CDKN2A mutation carriers with metastatic melanoma were evaluated